Clinical Trial

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

Study acronym: AB-LATE02
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC. In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor growth and metastatic escape in the context of percutaneous thermal ablation for small HCC. Local ablation of HCC is therefore an "ideal" setting for testing atezolizumab + bevacizumab in combination with ablation, with the aim of reducing the risk of recurrence.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2021-01-22; most recent amendment 2026-06-17.
Status change: Recruiting → Active, Not Recruiting 2026-06-17
Status change: Not Yet Recruiting → Recruiting 2021-01-28
Trial Details
NCT Number NCT04727307
Lead Sponsor University Hospital, Montpellier
Conditions Hepatocellular Carcinoma
Enrollment 202 participants
Start Date 2021-02-23
Primary Completion 2028-02 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-22